Skip to main content
OpenTrials
Completed

NCT Number: NCT04479813

Role of Sympathetic Activation in Ischemia Reperfusion Injury

This study is designed to assess the effect of forearm ischemia-reperfusion injury on sympathetic nerve activity. To determine whether reduced sympathetic responsiveness is a contributor to the protective effects of remote ischemic preconditioning. In addition it will assess whether pharmacologic inhibition of the sympathetic nervous system can ameliorate ischemia reperfusion injury induced endothelial dysfunction.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Central Sympathetic Nervous System Diseases Ischemia Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Dobney Hypertension Centre

Perth, Australia

About this study

This is a randomized single blind study where subjects will be allocated to undergo one of the 4 protocols. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

This medication acts by reducing the activity of nerves believed to be involved in the conditioning process. The placebo pill, designed to have no effect, will be used as a comparison. Comprehensive tests will occur which include Microneurography, Endothelial function ,Blood Sampling, Temporary block of arm blood flow and Remote conditioning

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy males, not on any medication, free of any history of metabolic, cardiovascular or cerebrovascular disease.

Exclusion criteria

  • smoker

Treatment and study plan

Moxonidine 0.2 MG

Drug

Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

Placebo

Other

Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

Primary outcomes

  1. change in muscle sympathetic nerve activity

    Time frame: 1 day

    Muscle sympathetic nerve activity assessed by microneurography

Secondary outcomes

  1. Endothelial Function using the EndoPat2000 device

    Time frame: 2 days

    Endothelial Function testing involves the measurement of pulse amplitude from the tip of each index finger at rest and after a period of occlusion using an arm cuff that is manually inflated to a level above that of the participant's Blood Pressure (BP).

Sponsors and collaborators

Lead sponsor

Royal Perth Hospital

Other

Registry information

Important dates

Study start
2015
Primary completion
2022
Study completion
2022
First posted
Jul 21, 2020
Registry last updated
Sep 29, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.